Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 22, 2006

Epix Pharmaceuticals’ Clinical Results Find Candidate May be More Useful for Depression than Anxiety

  • Epix Pharmaceuticals reported that top-line results from its Phase III trial of PRX-00023, a long-acting 5-HT1A agonist, show that PRX-00023 did not achieve a statistically significant improvement over placebo for the primary endpoint.

    The primary efficacy endpoint was change from baseline in Hamilton Rating Scale for Anxiety (HAM-A) compared to placebo. There was a trend in favor of patients treated with PRX-00023 in the HAM-A assessments. However, the outcome was potentially impacted by a higher than expected response in the placebo-treated patients.

    The data from this trial did show a statistically significant improvement from baseline in the Montgomery Asberg Depression Rating Scale (MADRS), compared to placebo. The MADRS, which measures symptoms of depression, was a secondary endpoint in this trial.

    “We are disappointed that treatment with PRX-00023 did not induce a statistically significant change in the HAM-A in patients with anxiety; however, we are encouraged by the MADRS data and will further analyze these results to better understand the potential benefits of PRX-00023 in patients with depression,” says Michael G. Kauffman, M.D., Ph.D., CEO.

    “Based on these top-line results, we plan to refocus our efforts away from anxiety to evaluate the benefit in depression more closely and assess opportunities for initiating a Phase III clinical trial in depression sooner than originally planned.”



Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »